ArticleThe Lancet regional health. Europe2026

Cost-effectiveness of pramipexole augmentation for acute phase and maintenance therapy of treatment-resistant depression compared to placebo augmentation: economic evaluation of the PAX-D randomised controlled trial.

Agata Łaszewska et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.